Thomas Areschoug
Corporate Officer/Principal en XINTELA AB .
Perfil
Thomas Areschoug was the founder of Minervax ApS, a company founded in 2010 where he held the title of Director.
He is currently working as the Chief Business Officer at Xintela AB since 2017.
In the past, he worked as the Manager-Business Development at Invest in Skane AB.
Cargos activos de Thomas Areschoug
| Empresas | Cargo | Inicio |
|---|---|---|
| XINTELA AB | Corporate Officer/Principal | 01/03/2017 |
Antiguos cargos conocidos de Thomas Areschoug.
| Empresas | Cargo | Fin |
|---|---|---|
Invest in Skane AB
 Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Corporate Officer/Principal | - |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Founder | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Empresas privadas | 2 |
|---|---|
Invest in Skane AB
Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Commercial Services |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Areschoug
